Navigation Links
GeneThera, Inc. Acquires Applied Genetics, S.A.
Date:1/25/2012

WESTMINSTER, Colo., Jan. 25, 2012 /PRNewswire/ -- GeneThera, Inc. (OTCQB: GTHR) announced today that it has acquired a majority ownership of Applied Genetics, a molecular diagnostic company based in Monterrey, Mexico. Applied Genetics is a molecular diagnostic company that focuses on commercializing molecular testing for Johne's disease in Mexico.

This acquisition is part of a broader strategy aimed at quickly initiating Applied Genetics revenue-generating operation.

Dr. Tony Milici, CEO of GeneThera and Interim President of Applied Genetics, commented on the news: "We are very pleased to have reached an agreement with the other shareholders of Applied Genetics to acquire a controlling interest in the company. We will continue our efforts to make GeneThera a leader in molecular diagnostic testing both in Mexico and South America."

Johne's disease is a global devastating and incurable disease of dairy cows, sheep, and goats caused by a bacterium called Mycobacterium Paratuberculosis sub. Avium, (MAP).   An overwhelming number of studies have shown that MAP is the causative agent of Crohn's disease in humans. Dairy products, contaminated with MAP, are the vehicles by which the infection spreads in the human intestine. Applied Genetics employs the use of GeneThera HerdCheck™ to test and control the spread of Johne's disease in Mexico.  HerdCheck™ is a proprietary molecular diagnostic system based on the use of high throughput robotics and Real time PCR.

About GeneThera, Inc.
GeneThera, Inc. is a molecular biotechnology company located in Westminster, Colorado. The Company's proprietary diagnostic solution is based on a genetic expression assay, GES™ and Johne's disease management system, HERDCHECK™, designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES™ and
'/>"/>

SOURCE GeneThera, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. [video] Dr. Tony Milici, Chairman and CEO of GeneThera, Inc., Discusses Worldwide Rights to E.Coli Vaccine on WallSt.nets 3-Minute Press Show
2. Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice
3. Safecor Health Acquires Unit-Dose Pharmaceutical Leader RSC
4. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
5. MediCult Acquires US-Based MidAtlantic Diagnostics to Further Strengthen ART Presence
6. Milestone Scientific Acquires Additional Patent Rights for Painless Injections and Resolves Related Litigations
7. Advanced Instruments Acquires D & F Control Systems Inc.
8. Circassia Acquires North American and Japanese Rights to Dopexamine
9. CPA Acquires Renowned German Patent Research Specialist, SVPG
10. Millstone Medical Outsourcing Acquires New Facility to Accommodate Growing Business, Provide Additional Clean Room Capacity
11. Affitech Acquires Pharmexas Diabody Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 27, 2015 The Medical Innovation Impact ... of regulation on medical innovation, has been developed at ... of Fairleigh Dickinson University’s ( FDU ) Rothman Institute ... pertains to new FDA (Food & Drug Administration) ... the approval of certain medical devices. , “The ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 The ... with the Max Planck Society establishing the ... Photonics. The center will link two of the world's ... will be only the third Max Planck Centre in ... international society for optics and photonics, was with ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 WORMS, ... Grace & Co. (NYSE: GRA) announces that its ... manufacturing practice (GMP) certification from EXCiPACT™, an independent ... pharmaceutical excipients. , All three Grace ... pharmaceutical grade excipient silica gels have now received ...
(Date:5/26/2015)... REDWOOD CITY , Kalifornien und HILDEN, ... QIAGEN Clinical Insight ... Interpretation von Genvarianten und die Erstellung dazugehöriger ... und ESHG     QIAGEN N.V. ... QIA) gab heute die Markteinführung von QIAGEN ...
Breaking Biology Technology:Medical Innovation Impact Index Launched at Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) under the Rothman Institute 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 3CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6
... performance in the U.S. during 2004. , ,We also took ... this investment as well as how the life science industry performed. ... at how the life science industry in the Midwest performed, that ... ,Still, I was able to ferret out some additional data ...
... the university's Center for Intelligent Maintenance Systems said ... in April. Professor Jay Lee told the Milwaukee Journal-Sentinel that ... not have good enough legal and other infrastructure to support ... said it would sell all the assets of its ...
... That is MAD as in mergers, acquisitions and divestitures. The value ... outpaced all of 1999 heretofore a record year for corporate ... a blockbuster as well. , , According to Business Week , ... 40 days of this year. In just the past few weeks ...
Cached Biology Technology:Midwest VC investment up in 2004, but number of deals down 2Midwest VC investment up in 2004, but number of deals down 3Staying sane in a MAD world 2Staying sane in a MAD world 3
(Date:5/20/2015)... 2015 Research ... the addition of the  "5-year Opportunity ... Market"  report to their offering.  ,     ... analyses trends in the iris recognition ... sectors, globally. Despite hardware pricing and ...
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
(Date:5/11/2015)... 11, 2015  Synaptics Incorporated (NASDAQ: SYNA ... today announced the appointment of Wajid Ali ... Officer, reporting to Rick Bergman , President ... Financial Officer, Kathleen Bayless , who announced ... Mr. Ali brings extensive financial management expertise to ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... by researchers David General of the Palawan State University , ... Zoology , Harvard University has led to the discovery of nine ... Philippines. Another two new genera were discovered by other researchers in ... jubilee issue of the open access journal Zookeys ...
... of the site of a spent nuclear fuel repository ... the International Journal of Environmental Technology and Management, the ... positive opinion on the location of such facilities than ... of nuclear waste around the globe are relatively small, ...
... Spanish . , Project PreDiCT-TB is ... the European pharmaceutical industry in the hopes of studying ... that affects nearly nine million people throughout the world. ... trials (,in vitro, and ,in vivo,) that will provide ...
Cached Biology News:An ant scientist's picnic: The highly diverse ant fauna of the Philippines 2Where to put nuclear waste? 2Research on improvements in diagnosing and treating tuberculosis 2Research on improvements in diagnosing and treating tuberculosis 3